Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

NCT00118144 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: bortezomib

Sponsor

National Cancer Institute (NCI)